Loading
A phase 2 trial of tislelizumab and capecitabine in colorectal cancer, run by Yanhong Deng, now recruiting.
Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer is a phase 2, randomised interventional study registered as NCT05360277 by Yanhong Deng, with a registry enrolment figure of 52 participants, started 2023-08-22 and due to reach its primary completion in 2025-02-28. Interventions recorded: Tislelizumab + Capecitabine; Best supportive care. Conditions listed: Metastatic Colorectal Cancer，NED. Primary outcome: Disease-free survival. Colorectal eligibility wording from the registry: "Surgery with integrated treatment for metastatic colorectal cancer (mCRC) and achieved a statute of no evidence of disease (NED), as determined by a multidisciplinary tumor board". Sites: China. No results are recorded here; the registry entry is the source.
Shares Tislelizumab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Tislelizumab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Capecitabine, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Capecitabine, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Tislelizumab, Capecitabine, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Tislelizumab, Capecitabine, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Tislelizumab, Capecitabine, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Tislelizumab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.